A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
09 Jan 2024
09 Jan 2024
Historique:
received:
09
08
2023
accepted:
19
12
2023
revised:
08
11
2023
medline:
10
1
2024
pubmed:
10
1
2024
entrez:
10
1
2024
Statut:
aheadofprint
Résumé
Irreversible electroporation (IRE) is a novel technique to treat localized prostate cancer with the aim of achieving oncological control while reducing related side effects. We present the outcomes of localized prostate cancer treated with IRE from a multi-center prospective registry. Men with histologically confirmed prostate cancer were recruited to receive IRE. All the patients were proposed for prostate biopsy at 1-year post-IRE ablation. The functional outcomes were measured by the International Prostate Symptom Score (IPSS) and International Index of Erectile Function (IIEF-5) questionnaires. The safety of IRE was graded by the treatment-related adverse events (AEs) according to the Common Terminology Criteria for Adverse Events (CTCAE). 411 patients were recruited in this study from July 2015 to April 2020. The median follow-up time was 24 months (IQR 15-36). 116 patients underwent repeat prostate biopsy during 12-18 months after IRE. Clinically significant prostate cancer (Gleason ≥ 3 + 4) was detected in 24.1% (28/116) of the patients; any grade prostate cancers were found in 59.5% (69/116) of the patients. The IPSS score increased significantly from 7.1 to 8.2 (p = 0.015) at 3 months but decreased to 6.1 at 6 months (p = 0.017). Afterwards, the IPSS level remained stable during follow-up. The IIEF-5 score decreased at 3 months from 16.0 to 12.1 (p < 0.001) and then maintained equable afterwards. The rate of AEs was 1.8% at 3 months and then dropped to less than 1% at 6 months and remained stable until 48 months after IRE. Major AEs (Grade 3 or above) were rare. For men with localized prostate cancer, IRE could achieve good urinary and sexual function outcomes and a reasonable oncological result. The real-world data are consistent with earlier studies, including recently published randomized controlled studies. The long-term oncological results need further investigation and follow-up.
Sections du résumé
BACKGROUND
BACKGROUND
Irreversible electroporation (IRE) is a novel technique to treat localized prostate cancer with the aim of achieving oncological control while reducing related side effects. We present the outcomes of localized prostate cancer treated with IRE from a multi-center prospective registry.
METHODS
METHODS
Men with histologically confirmed prostate cancer were recruited to receive IRE. All the patients were proposed for prostate biopsy at 1-year post-IRE ablation. The functional outcomes were measured by the International Prostate Symptom Score (IPSS) and International Index of Erectile Function (IIEF-5) questionnaires. The safety of IRE was graded by the treatment-related adverse events (AEs) according to the Common Terminology Criteria for Adverse Events (CTCAE).
RESULTS
RESULTS
411 patients were recruited in this study from July 2015 to April 2020. The median follow-up time was 24 months (IQR 15-36). 116 patients underwent repeat prostate biopsy during 12-18 months after IRE. Clinically significant prostate cancer (Gleason ≥ 3 + 4) was detected in 24.1% (28/116) of the patients; any grade prostate cancers were found in 59.5% (69/116) of the patients. The IPSS score increased significantly from 7.1 to 8.2 (p = 0.015) at 3 months but decreased to 6.1 at 6 months (p = 0.017). Afterwards, the IPSS level remained stable during follow-up. The IIEF-5 score decreased at 3 months from 16.0 to 12.1 (p < 0.001) and then maintained equable afterwards. The rate of AEs was 1.8% at 3 months and then dropped to less than 1% at 6 months and remained stable until 48 months after IRE. Major AEs (Grade 3 or above) were rare.
CONCLUSION
CONCLUSIONS
For men with localized prostate cancer, IRE could achieve good urinary and sexual function outcomes and a reasonable oncological result. The real-world data are consistent with earlier studies, including recently published randomized controlled studies. The long-term oncological results need further investigation and follow-up.
Identifiants
pubmed: 38195916
doi: 10.1038/s41391-023-00783-y
pii: 10.1038/s41391-023-00783-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Wallis CJD, Glaser A, Hu JC, Huland H, Lawrentschuk N, Moon D, et al. Survival and complications following surgery and radiation for localized prostate cancer: an International Collaborative Review. Eur Urol. 2018;73:11–20.
doi: 10.1016/j.eururo.2017.05.055
pubmed: 28610779
Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ, et al. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received. Eur Urol. 2020;77:320–30.
doi: 10.1016/j.eururo.2019.10.030
pubmed: 31771797
Onik G, Mikus P, Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat. 2007;6:295–300.
doi: 10.1177/153303460700600405
pubmed: 17668936
van den Bos W, de Bruin DM, Muller BG, Varkarakis IM, Karagiannis AA, Zondervan PJ, et al. The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol. BMJ Open. 2014;4:e006382.
doi: 10.1136/bmjopen-2014-006382
pubmed: 25354827
pmcid: 4216863
van den Bos W, de Bruin DM, Jurhill RR, Savci-Heijink CD, Muller BG, Varkarakis IM, et al. The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients. World J Urol. 2016;34:657–64.
doi: 10.1007/s00345-015-1661-x
pubmed: 26296371
Scheltema MJ, Geboers B, Blazevski A, Doan P, Katelaris A, Agrawal S, et al. Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer. BJU Int. 2023;131:6–13.
doi: 10.1111/bju.15946
pubmed: 36495481
Guenther E, Klein N, Zapf S, Weil S, Schlosser C, Rubinsky B, et al. Prostate cancer treatment with Irreversible Electroporation (IRE): safety, efficacy and clinical experience in 471 treatments. PLoS One. 2019;14:e0215093.
doi: 10.1371/journal.pone.0215093
pubmed: 30986263
pmcid: 6464181
Wang H, Xue W, Yan W, Yin L, Dong B, He B, et al. Extended focal ablation of localized prostate cancer with high-frequency irreversible electroporation: a nonrandomized controlled trial. JAMA Surg. 2022;157:693–700.
doi: 10.1001/jamasurg.2022.2230
pubmed: 35793110
pmcid: 9260646
Blazevski A, Scheltema MJ, Yuen B, Masand N, Nguyen TV, Delprado W, et al. Oncological and quality-of-life outcomes following focal irreversible electroporation as primary treatment for localised prostate cancer: a biopsy-monitored prospective cohort. Eur Urol Oncol. 2020;3:283–90.
doi: 10.1016/j.euo.2019.04.008
pubmed: 31103721
Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, et al. New and established technology in focal ablation of the prostate: a systematic review. Eur Urol. 2017;71:17–34.
doi: 10.1016/j.eururo.2016.08.044
pubmed: 27595377
Olweny EO, Kapur P, Tan YK, Park SK, Adibi M, Cadeddu JA. Irreversible electroporation: evaluation of nonthermal and thermal ablative capabilities in the porcine kidney. Urology. 2013;81:679–84.
doi: 10.1016/j.urology.2012.11.026
pubmed: 23290141
Kwon JH, Kim MD, Kim SH, Lee EW, Kahlid SA. Effects of irreversible electroporation on femoral nerves in a rabbit model. Minim Invasive Ther Allied Technol. 2022;31:306–12.
doi: 10.1080/13645706.2020.1799820
pubmed: 32744129
de la Rosette J, Dominguez-Escrig J, Zhang K, Teoh J, Barret E, Ramon-Borja JC, et al. A multicenter, randomized, single-blind, 2-arm intervention study evaluating the adverse events and quality of life after irreversible electroporation for the ablation of localized low-intermediate risk prostate cancer. J Urol. 2023;209:347–53.
doi: 10.1097/JU.0000000000003051
pubmed: 36441776
Zhang K, Teoh J, Laguna P, Dominguez-Escrig J, Barret E, Ramon-Borja JC, et al. Effect of focal vs extended irreversible electroporation for the ablation of localized low- or intermediate-risk prostate cancer on early oncological control: a randomized clinical trial. JAMA Surg. 2023;158:343–9.
Hopstaken JS, Bomers JGR, Sedelaar MJP, Valerio M, Fütterer JJ, Rovers MM. An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years? Eur Urol. 2022;81:5–33.
doi: 10.1016/j.eururo.2021.08.005
pubmed: 34489140
Bokhorst LP, Valdagni R, Rannikko A, Kakehi Y, Pickles T, Bangma CH, et al. A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol. 2016;70:954–60.
doi: 10.1016/j.eururo.2016.06.007
pubmed: 27329565
Gill IS, Azzouzi AR, Emberton M, Coleman JA, Coeytaux E, Scherz A, et al. Randomized trial of partial gland ablation with vascular targeted phototherapy versus active surveillance for low risk prostate cancer: extended followup and analyses of effectiveness. J Urol. 2018;200:786–93.
doi: 10.1016/j.juro.2018.05.121
pubmed: 29864437
pmcid: 6786489
Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol. 2015;68:438–50.
doi: 10.1016/j.eururo.2014.11.037
pubmed: 25480312
Geboers B, Gondoputro W, Thompson JE, Reesink DJ, van Riel L, Zhang D, et al. Diagnostic accuracy of multiparametric magnetic resonance imaging to detect residual prostate cancer following irreversible electroporation-a multicenter validation study. Eur Urol Focus. 2022;8:1591–8.
Abreu AL, Kaneko M, Cacciamani GE, Lebastchi AH. Focal therapy for prostate cancer: getting ready for prime time. Eur Urol. 2022;81:34–6.
doi: 10.1016/j.eururo.2021.10.005
pubmed: 34740501